Click here to close now.




















Welcome!

News Feed Item

Coronary Vasospasm Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Coronary Vasospasm Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/648928/Coronary-Vasospasm-Global-Clinical-Trials-Review-H2-2014.html

Coronary Vasospasm Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Coronary Vasospasm Global Clinical Trials Review, H2, 2014" provides data on the Coronary Vasospasm clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Vasospasm. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Vasospasm. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Coronary Vasospasm 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Coronary Vasospasm 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Coronary Vasospasm Therapeutics Clinical Trials 25
Prominent Drugs 26
Clinical Trial Profiles 27
Clinical Trial Overview of Top Companies 27
Pfizer Inc. 27
Clinical Trial Overview of Pfizer Inc. 27
Clinical Trial Overview of Top Institutes / Government 28
Japanese Coronary Spasm Association 28
Clinical Trial Overview of Japanese Coronary Spasm Association 28
Robert Bosch Medical Center 29
Clinical Trial Overview of Robert Bosch Medical Center 29
Kyorin University 30
Clinical Trial Overview of Kyorin University 30
Kumamoto University 31
Clinical Trial Overview of Kumamoto University 31
National Institute of Health and Medical Research 32
Clinical Trial Overview of National Institute of Health and Medical Research 32
University of Nebraska 33
Clinical Trial Overview of University of Nebraska 33
Korea University 34
Clinical Trial Overview of Korea University 34
University Hospital Basel 35
Clinical Trial Overview of University Hospital Basel 35
Washington University School of Medicine 36
Clinical Trial Overview of Washington University School of Medicine 36
University of California, San Francisco 37
Clinical Trial Overview of University of California, San Francisco 37
Five Key Clinical Profiles 38
Appendix 55
Abbreviations 55
Definitions 55
Research Methodology 56
Secondary Research 56
About GlobalData 57
Contact Us 57
Disclaimer 57
Source 57

List of Tables
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Region, 2014* 6
Coronary Vasospasm Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Coronary Vasospasm Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Coronary Vasospasm Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Coronary Vasospasm Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Coronary Vasospasm Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 13
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 16
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Coronary Vasospasm Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Coronary Vasospasm Therapeutics, Global, Suspended Clinical Trials, 2014* 21
Coronary Vasospasm Therapeutics, Global, Withdrawn Clinical Trials, 2014* 21
Coronary Vasospasm Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Coronary Vasospasm Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Coronary Vasospasm Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Coronary Vasospasm Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 25
Coronary Vasospasm Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 26
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 27
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Japanese Coronary Spasm Association, 2014* 28
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Robert Bosch Medical Center, 2014* 29
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Kyorin University, 2014* 30
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Kumamoto University, 2014* 31
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Health and Medical Research, 2014* 32
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Nebraska, 2014* 33
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Korea University, 2014* 34
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Basel, 2014* 35
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 36
Coronary Vasospasm Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 37

List of Figures
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Coronary Vasospasm Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Coronary Vasospasm Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Coronary Vasospasm Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Coronary Vasospasm Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 13
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Coronary Vasospasm Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Coronary Vasospasm to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 16
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Coronary Vasospasm Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Coronary Vasospasm Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Coronary Vasospasm Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Coronary Vasospasm Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
Coronary Vasospasm Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
GlobalData Methodology 56

Read the full report:
Coronary Vasospasm Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/648928/Coronary-Vasospasm-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Cloud and datacenter migration innovator AppZero has joined the Microsoft Enterprise Cloud Alliance Program. AppZero is a fast, flexible way to move Windows Server applications from any source machine – physical or virtual – to any destination server, in any cloud or datacenter, using its patented container technology. AppZero’s container is also called a Virtual Application Appliance (VAA). To facilitate Microsoft Azure onboarding, AppZero has two purpose-built offerings: AppZero SP for Azure,...
Organizations from small to large are increasingly adopting cloud solutions to deliver essential business services at a much lower cost. According to cyber security experts, the frequency and severity of cyber-attacks are on the rise, causing alarm to businesses and customers across a variety of industries. To defend against exploits like these, a company must adopt a comprehensive security defense strategy that is designed for their business. In 2015, organizations such as United Airlines, Sony...
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Consumer IoT applications provide data about the user that just doesn’t exist in traditional PC or mobile web applications. This rich data, or “context,” enables the highly personalized consumer experiences that characterize many consumer IoT apps. This same data is also providing brands with unprecedented insight into how their connected products are being used, while, at the same time, powering highly targeted engagement and marketing opportunities. In his session at @ThingsExpo, Nathan Trel...
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
Everyone talks about continuous integration and continuous delivery but those are just two ends of the pipeline. In the middle of DevOps is continuous testing (CT), and many organizations are struggling to implement continuous testing effectively. After all, without continuous testing there is no delivery. And Lab-As-A-Service (LaaS) enhances the CT with dynamic on-demand self-serve test topologies. CT together with LAAS make a powerful combination that perfectly serves complex software developm...
Through WebRTC, audio and video communications are being embedded more easily than ever into applications, helping carriers, enterprises and independent software vendors deliver greater functionality to their end users. With today’s business world increasingly focused on outcomes, users’ growing calls for ease of use, and businesses craving smarter, tighter integration, what’s the next step in delivering a richer, more immersive experience? That richer, more fully integrated experience comes ab...
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and a...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ab...
WSM International, the pioneer and leader in server migration services, has announced an agreement with WHOA.com, a leader in providing secure public, private and hybrid cloud computing services. Under terms of the agreement, WSM will provide migration services to WHOA.com customers to relocate some or all of their applications, digital assets, and other computing workloads to WHOA.com enterprise-class, secure cloud infrastructure. The migration services include detailed evaluation and planning...
In today's digital world, change is the one constant. Disruptive innovations like cloud, mobility, social media, and the Internet of Things have reshaped the market and set new standards in customer expectations. To remain competitive, businesses must tap the potential of emerging technologies and markets through the rapid release of new products and services. However, the rigid and siloed structures of traditional IT platforms and processes are slowing them down – resulting in lengthy delivery ...
The Internet of Things (IoT) is about the digitization of physical assets including sensors, devices, machines, gateways, and the network. It creates possibilities for significant value creation and new revenue generating business models via data democratization and ubiquitous analytics across IoT networks. The explosion of data in all forms in IoT requires a more robust and broader lens in order to enable smarter timely actions and better outcomes. Business operations become the key driver of I...
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
A producer of the first smartphones and tablets, presenter Lee M. Williams will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ETwater. In his session at @ThingsExpo, Lee Williams, COO of ETwater, will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ET...